

Dupilumab (Dupixent) Induction Followed by Maintenance Every 2 Weeks (Adult Dosing)

Dupilumab (Dupixent) 600 mg followed by maintenance 300 mg every 2 weeks

Protocol Types

Infusion Treatment 1, Infusion Treatment 2, Infusion Treatment 3, Infusion Treatment 4

Patient name: _____ DOB: _____

Please include: ☐ Patient face sheet ☐ Insurance authorization (if other than Medicaid or non-Advantage Medicare)

Diagnosis: _____

Review: Every 358 days

Orders

	Interval	Defer Until	Duration
Provider Communication			
☒ Provider communication	Every visit		Until discontinued
Until discontinued Starting when released Until Specified Conjunctivitis and keratitis have been reported.			

Avoid use of live vaccines in patients treated with dupilumab.

Nursing Orders

☒ Nursing communication	Every visit		Until discontinued
Until discontinued Starting when released Until Specified Advise patient to report signs/symptoms of hypersensitivity, including urticaria or symptoms of serum sickness or serum sickness-like reactions.			

Advise patient to report new onset or worsening eye symptoms, including conjunctivitis, keratitis, or blepharitis.

Advise patient with comorbid asthma not to adjust or discontinue asthma treatment without consultation with a physician.

Therapeutic Medications

☒ dupilumab (Dupixent) injection 600 mg	Once		1 treatment
600 mg, subcutaneous, Once, Starting when released Prior to administration, remove prefilled syringe from the refrigerator and allow to warm at room temperature for 45 minutes.			

Administer subcutaneously into the upper arm, thigh, or abdomen (avoiding areas within 2 inches of navel).
Rotate injection site with each injection. Do not inject into skin that is tender, damaged, bruised, or scarred.

☒ dupilumab (Dupixent) injection 300 mg	Every 14 days	S+14	Until discontinued
300 mg, subcutaneous, Once, Starting when released Prior to administration, remove prefilled syringe from the refrigerator and allow to warm at room temperature for 45 minutes.			

	Interval	Defer Until	Duration
Administer subcutaneously into the upper arm, thigh, or abdomen (avoiding areas within 2 inches of navel). Rotate injection site with each injection. Do not inject into skin that is tender, damaged, bruised, or scarred.			
Emergency Medications			
☒ Nursing communication	PRN		Until discontinued
STAT, Until discontinued Starting when released Until Specified			
If hypersensitivity reaction occurs, stop infusion IMMEDIATELY and CALL provider.			
☒ Vital Signs	PRN		Until discontinued
STAT, Every 15 min Starting when released			
If a hypersensitivity reaction occurs, perform vital signs every 15 minutes for one hour, then every 30 minutes for 2 hours.			
☒ Nursing communication	PRN		Until discontinued
Once Starting when released			
If hypersensitivity reaction occurs:			
- Elevate head of bed 30 degrees and place patient's head at 30 degree angle if possible			
- Start 2 liters oxygen per nasal cannula and maintain airway			
- Change and maintain IV line with 1000 mL 0.9% Normal Saline			
☒ sodium chloride 0.9 % infusion	PRN		Until discontinued
30 mL/hr, intravenous, Continuous PRN, KVO, Starting when released, for 1 day			
☒ albuterol 2.5 mg /3 mL (0.083 %) nebulizer solution 2.5 mg	PRN		Until discontinued
2.5 mg, nebulization, Every 4 hours PRN, Hypersensitivity reaction, Starting when released, for 1 day			
☒ albuterol HFA 90 mcg/act inhaler 2 puff	PRN		Until discontinued
2 puff, inhalation, Every 4 hours PRN, Hypersensitivity reaction, Starting when released, for 1 day			
SHAKE WELL			
☒ acetaminophen (Tylenol) tablet 650 mg	PRN		Until discontinued
650 mg, oral, Once as needed, fever, GREATER THAN or EQUAL TO 38 C, Starting when released, for 1 dose			
For mild/moderate reaction: flushing, rash, pruritus			
☒ diphenhydramine (BENADryl) injection 25 mg	PRN		Until discontinued
25 mg, intravenous, Administer over: 2 Minutes, Once as needed, Hypersensitivity reaction, Starting when released, for 1 dose			
For mild/moderate reaction: flushing, rash, pruritus			
☒ diphenhydramine (BENADryl) injection 50 mg	PRN		Until discontinued
50 mg, intravenous, Administer over: 2 Minutes, Once as needed, Hypersensitivity reaction, Starting when released, for 1 dose			
For severe reaction: respiratory distress, stridor, wheezing, hypotension (SBP LESS THAN 100 mm Hg)			
☒ hydrocortisone sodium succinate (Solu-CORTEF) injection 100 mg	PRN		Until discontinued
100 mg, intravenous, Once as needed, Hypersensitivity reaction, Starting when released, for 1 dose			
For mild/moderate reaction: flushing, rash, pruritus			
- OR -			
For severe reaction: respiratory distress, stridor, wheezing, hypotension (SBP LESS THAN 100 mm Hg)			
☒ EPINEPHrine (EpiPen;Adrenalin) injection solution 0.3 mg	PRN		Until discontinued
0.3 mg, intramuscular, Once as needed, Hypersensitivity reaction, Starting when released, for 1 dose			
For severe reaction: respiratory distress, stridor, wheezing, hypotension (SBP LESS THAN 100 mm Hg)			

Appointment Requests

☒ Infusion Appointment Request	Once		1 treatment
Status: Future, Expected: S, Expires: S+365, Sched. Duration: 30 minutes, Sched. Tolerance: Schedule appointment at most 3 days before or at most 3 days after			
☒ Infusion Appointment Request	Every 14 days	S+14	Until discontinued

Interval

Defer Until

Duration

Status: Future, Expected: S, Expires: S+365, Sched. Duration: 30 minutes, Sched. Tolerance: Schedule appointment at most 3 days before or at most 3 days after

*Provider signature

Provider printed name

*Date

Time

*Provider phone#

***Denotes field that must be completed by healthcare worker**